Advancements and Applications of Liquid Biopsies in Oncology: A Narrative Review

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2023 Sep 1

PMID 37654932

Authors

Jawad Noor

Ahtshamullah Chaudhry

Riwad Noor

Saima Batool

Affiliations

Soon will be listed here.

Abstract

According to the World Health Organization (WHO), nearly 10 million people died from cancer worldwide in 2020, making it the leading cause of mortality. Liquid biopsies, which provide non-invasive and real-time monitoring of tumor dynamics, have evolved into innovative diagnostic techniques in the field of oncology. Liquid biopsies offer important insights into tumor heterogeneity, treatment response, minimum residual disease identification, and personalized treatment of cancer through the analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), extracellular vesicles, and microRNAs. They offer several advantages over traditional tissue biopsies, such as being less invasive, more convenient, more representative of tumor heterogeneity and dynamics, and more informative for guiding personalized treatment decisions. Liquid biopsies are being utilized increasingly in clinical oncology, particularly for patients with metastatic disease who require ongoing monitoring and treatment modification. In this narrative review article, we review the latest developments of liquid biopsy technologies, their applications and limitations, and their potential to transform diagnosis, prognosis, and management of cancer patients.

Citing Articles

The Histomorphology to Molecular Transition: Exploring the Genomic Landscape of Poorly Differentiated Epithelial Endometrial Cancers.

Molefi T, Mabonga L, Hull R, Mwazha A, Sebitloane M, Dlamini Z Cells. 2025; 14(5).

PMID: 40072110 PMC: 11898822. DOI: 10.3390/cells14050382.

[Progression and application of circulating tumor DNA in lymphoma].

Huang D, Zhang X, Rao J Zhonghua Xue Ye Xue Za Zhi. 2024; 45(9):878-882.

PMID: 39414617 PMC: 11518914. DOI: 10.3760/cma.j.cn121090-20240528-00197.

Precision medicine in breast cancer (Review).

Papalexis P, Georgakopoulou V, Drossos P, Thymara E, Nonni A, Lazaris A Mol Clin Oncol. 2024; 21(5):78.

PMID: 39246849 PMC: 11375768. DOI: 10.3892/mco.2024.2776.

Exploring the Immunological Profile in Breast Cancer: Recent Advances in Diagnosis and Prognosis through Circulating Tumor Cells.

Kotsifaki A, Maroulaki S, Armakolas A Int J Mol Sci. 2024; 25(9).

PMID: 38732051 PMC: 11084220. DOI: 10.3390/ijms25094832.

Circulating Cancer-Associated Macrophage-like Cells as a Blood-Based Biomarker of Response to Immune Checkpoint Inhibitors.

Magri V, De Renzi G, Marino L, De Meo M, Siringo M, Gelibter A Int J Mol Sci. 2024; 25(7).

PMID: 38612563 PMC: 11011814. DOI: 10.3390/ijms25073752.

References

Xiao J, Sharma U, Arab A, Miglani S, Bhalla S, Suguru S . Propagated Circulating Tumor Cells Uncover the Potential Role of NFκB, EMT, and TGFβ Signaling Pathways and in Metastasis. Cancers (Basel). 2023; 15(6). PMC: 10046547. DOI: 10.3390/cancers15061831. View

Birbo B, Madu E, Madu C, Jain A, Lu Y . Role of HSP90 in Cancer. Int J Mol Sci. 2021; 22(19). PMC: 8508648. DOI: 10.3390/ijms221910317. View

Buchbinder E, Desai A . CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol. 2015; 39(1):98-106. PMC: 4892769. DOI: 10.1097/COC.0000000000000239. View

Li L, Zhang L, Montgomery K, Jiang L, Lyon C, Hu T . Advanced technologies for molecular diagnosis of cancer: State of pre-clinical tumor-derived exosome liquid biopsies. Mater Today Bio. 2023; 18:100538. PMC: 9812720. DOI: 10.1016/j.mtbio.2022.100538. View

Min J, Zhou H, Jiang S, Yu H . A Review of Circulating Tumor DNA in the Diagnosis and Monitoring of Esophageal Cancer. Med Sci Monit. 2022; 28:e934106. PMC: 8886734. DOI: 10.12659/MSM.934106. View

de Miranda F, Barauna V, Dos Santos L, Costa G, Vassallo P, Campos L . Properties and Application of Cell-Free DNA as a Clinical Biomarker. Int J Mol Sci. 2021; 22(17). PMC: 8431421. DOI: 10.3390/ijms22179110. View

Thepmalee C, Panya A, Junking M, Chieochansin T, Yenchitsomanus P . Inhibition of IL-10 and TGF-β receptors on dendritic cells enhances activation of effector T-cells to kill cholangiocarcinoma cells. Hum Vaccin Immunother. 2018; 14(6):1423-1431. PMC: 6037468. DOI: 10.1080/21645515.2018.1431598. View

IJzerman M, de Boer J, Azad A, Degeling K, Geoghegan J, Hewitt C . Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late. Diagnostics (Basel). 2021; 11(1). PMC: 7826562. DOI: 10.3390/diagnostics11010103. View

Adams L, Lymp J, Sauver J, Sanderson S, Lindor K, Feldstein A . The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005; 129(1):113-21. DOI: 10.1053/j.gastro.2005.04.014. View

10.

Freitas A, Causin R, Varuzza M, Calfa S, Hidalgo Filho C, Komoto T . Liquid Biopsy as a Tool for the Diagnosis, Treatment, and Monitoring of Breast Cancer. Int J Mol Sci. 2022; 23(17). PMC: 9456236. DOI: 10.3390/ijms23179952. View

11.

Raufi A, May M, Hadfield M, Seyhan A, El-Deiry W . Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer. Int J Mol Sci. 2023; 24(4). PMC: 9958987. DOI: 10.3390/ijms24044238. View

12.

Michela B . Liquid Biopsy: A Family of Possible Diagnostic Tools. Diagnostics (Basel). 2021; 11(8). PMC: 8394215. DOI: 10.3390/diagnostics11081391. View

13.

Chen Q, Zou J, He Y, Pan Y, Yang G, Zhao H . A narrative review of circulating tumor cells clusters: A key morphology of cancer cells in circulation promote hematogenous metastasis. Front Oncol. 2022; 12:944487. PMC: 9434215. DOI: 10.3389/fonc.2022.944487. View

14.

Kilgour E, Rothwell D, Brady G, Dive C . Liquid Biopsy-Based Biomarkers of Treatment Response and Resistance. Cancer Cell. 2020; 37(4):485-495. DOI: 10.1016/j.ccell.2020.03.012. View

15.

Cheng Y, Zhang T, Xu Q . Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. MedComm (2020). 2022; 2(4):692-729. PMC: 8706764. DOI: 10.1002/mco2.105. View

16.

Lone S, Nisar S, Masoodi T, Singh M, Rizwan A, Hashem S . Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol Cancer. 2022; 21(1):79. PMC: 8932066. DOI: 10.1186/s12943-022-01543-7. View

17.

Mikolajczyk S, Millar L, Tsinberg P, Coutts S, Zomorrodi M, Pham T . Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral Blood. J Oncol. 2011; 2011:252361. PMC: 3090615. DOI: 10.1155/2011/252361. View

18.

Hofmann L, Sallinger K, Haudum C, Smolle M, Heitzer E, Moser T . A Multi-Analyte Approach for Improved Sensitivity of Liquid Biopsies in Prostate Cancer. Cancers (Basel). 2020; 12(8). PMC: 7465186. DOI: 10.3390/cancers12082247. View

19.

Anaparthy N, Ho Y, Martelotto L, Hammell M, Hicks J . Single-Cell Applications of Next-Generation Sequencing. Cold Spring Harb Perspect Med. 2019; 9(10). PMC: 6771363. DOI: 10.1101/cshperspect.a026898. View

20.

Klein E, Richards D, Cohn A, Tummala M, Lapham R, Cosgrove D . Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021; 32(9):1167-1177. DOI: 10.1016/j.annonc.2021.05.806. View